查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1638843

年龄相关性黄斑部病变市场机会、成长动力、产业趋势分析与预测 2024 - 2032

Age-related Macular Degeneration Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2024 - 2032
出版日期: | 出版商: Global Market Insights Inc. | 英文 150 Pages | 商品交期: 2-3个工作天内

价格
简介目录

2023 年，全球老年黄斑部病变市场估值为 104 亿美元，预计 2024 年至 2032 年复合年增长率为 9.8%。的一部分，负责敏锐和直接的视力。这种情况主要影响老年人，随着全球人口老化，这种情况变得越来越普遍。

市场依产品分为 Eylea、Lucentis、Beovu、Vabysmo、Syfovre、Avastin 等治疗方法。 Eylea 于 2023 年占据市场主导地位，营收达 44 亿美元。其广泛采用源自于经过验证的临床疗效、一致的安全性结果以及每月或每两个月给药选择的灵活性。这种适应性提高了患者的依从性，这对于治疗 AMD 等慢性疾病至关重要。

AMD依疾病类型进一步分为湿性AMD和干性AMD。湿性 AMD 到 2023 年的收入为 85 亿美元，是老年人视力障碍的主要原因。这种疾病涉及视网膜下方异常的血管生长，导致液体渗漏和中心视力丧失。针对血管内皮生长因子（VEGF）的治疗是控制疾病进展的主要介入措施。全球老化人口不断增加，加上预期寿命不断延长，导致湿性 AMD 病例激增，因此更需要有效的视力保护疗法。解决频繁注射负担的创新正在获得关注，为患者提供更方便的给药方案并提高治疗依从性。

市场范围
开始年份 2023年
预测年份 2024-2032
起始值 104 亿美元
预测值 239 亿美元
复合年增长率 9.8%

从地区来看，2023 年美国市场规模为 42 亿美元，预计在预测期内复合年增长率为 9.9%。美国老年人口的增加推动了对先进 AMD 治疗方案的需求。凭藉强大的生物製药产业，该国处于开发创新 AMD 疗法的前沿，包括基因疗法、缓释药物配方和联合治疗。随着 AMD 盛行率的不断上升，这些进步旨在为管理 AMD 提供更有效、更易于使用的解决方案。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

  • 产业生态系统分析
  • 产业影响力
    • 成长动力
      • AMD 盛行率上升
      • 人口老化的成长
      • 治疗方案的进步
      • 提高认识和早期诊断
    • 产业陷阱与挑战
      • 治疗费用高
      • 玻璃体内注射併发症的风险
  • 成长潜力分析
  • 监管环境
  • 技术景观
    • 核心技术
    • 邻近技术
  • 未来市场趋势
  • 专利分析
  • 管道分析
  • 临床试验情况
  • 波特的分析
  • PESTEL分析

第 4 章：竞争格局

  • 介绍
  • 公司市占率分析
  • 公司矩阵分析
  • 主要市场参与者的竞争分析
  • 竞争定位矩阵
  • 战略仪表板

第 5 章：市场估计与预测：按产品分类，2021 - 2032 年

  • 主要趋势
  • 艾利亚
  • 卢森提斯
  • 贝奥武
  • 瓦比斯莫
  • 西福弗尔
  • 阿瓦斯汀
  • 其他产品

第 6 章：市场估计与预测：按疾病类型，2021 - 2032

  • 主要趋势
  • 湿AMD
  • 干性AMD

第 7 章：市场估计与预测：按年龄划分，2021 - 2032

  • 主要趋势
  • 50-64岁
  • 65-74岁
  • 75及以上

第 8 章：市场估计与预测：按配销通路，2021 - 2032 年

  • 主要趋势
  • 医院药房
  • 专业药房
  • 电子商务

第 9 章：市场估计与预测：按地区，2021 - 2032

  • 主要趋势
  • 北美洲
    • 我们
    • 加拿大
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 义大利
    • 荷兰
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 澳洲
    • 韩国
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿联酋

第 10 章：公司简介

  • Adverum Biotechnologies
  • Alkeus Pharmaceuticals
  • Amgen
  • Astellas Pharma
  • Bausch Health Companies
  • Bayer AG
  • Biogen
  • Coherus BioSciences
  • F. Hoffmann-La Roche
  • Kodiak Sciences
  • Novartis AG
  • Pfizer
  • Regeneron Pharmaceuticals
  • Sandoz Group AG
  • STADA Arzneimittel AG
简介目录
Product Code: 12195

The Global Age-related Macular Degeneration Market was valued at USD 10.4 billion in 2023 and is expected to grow at a CAGR of 9.8% from 2024 to 2032. AMD is a progressive eye condition that affects central vision due to damage to the macula, the part of the retina responsible for sharp and direct vision. This condition primarily impacts older adults, becoming increasingly prevalent as the global population ages.

The market is categorized by product into treatments such as Eylea, Lucentis, Beovu, Vabysmo, Syfovre, Avastin, and others. Eylea dominated the market in 2023, generating USD 4.4 billion in revenue. Its widespread adoption stems from proven clinical efficacy, consistent safety results, and the flexibility of monthly or bi-monthly dosing options. This adaptability improves patient compliance, which is essential for managing chronic conditions like AMD.

AMD is further classified by disease type into wet and dry AMD. Wet AMD, which accounted for USD 8.5 billion in revenue in 2023, represents the leading cause of vision impairment among older adults. This disease involves abnormal blood vessel growth beneath the retina, resulting in fluid leakage and central vision loss. Treatments targeting vascular endothelial growth factor (VEGF) are the primary intervention for controlling disease progression. The rising global aging population, coupled with increasing life expectancy, has led to a surge in wet AMD cases, intensifying the need for effective, vision-preserving therapies. Innovations addressing the burden of frequent injections are gaining traction, offering patients more convenient dosing schedules and improving treatment adherence.

Market Scope
Start Year2023
Forecast Year2024-2032
Start Value$10.4 Billion
Forecast Value$23.9 Billion
CAGR9.8%

Regionally, the U.S. market accounted for USD 4.2 billion in 2023 and is anticipated to grow at a CAGR of 9.9% during the forecast period. The increasing elderly population in the U.S. drives demand for advanced AMD treatment options. With a robust biopharmaceutical industry, the country is at the forefront of developing innovative AMD therapies, including gene therapies, extended-release drug formulations, and combination treatments. These advancements aim to provide more effective and accessible solutions for managing AMD as its prevalence continues to rise.

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Market scope & definitions
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates & calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Rising prevalence of AMD
      • 3.2.1.2 Growth in aging population
      • 3.2.1.3 Advancements in treatment options
      • 3.2.1.4 Increased awareness and early diagnosis
    • 3.2.2 Industry pitfalls & challenges
      • 3.2.2.1 High cost of treatment
      • 3.2.2.2 Risk of complications from intravitreal injections
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
  • 3.5 Technological landscape
    • 3.5.1 Core technologies
    • 3.5.2 Adjacent technologies
  • 3.6 Future market trends
  • 3.7 Patent analysis
  • 3.8 Pipeline analysis
  • 3.9 Clinical trial landscape
  • 3.10 Porter's analysis
  • 3.11 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company market share analysis
  • 4.3 Company matrix analysis
  • 4.4 Competitive analysis of major market players
  • 4.5 Competitive positioning matrix
  • 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2032 ($ Mn)

  • 5.1 Key trends
  • 5.2 Eylea
  • 5.3 Lucentis
  • 5.4 Beovu
  • 5.5 Vabysmo
  • 5.6 Syfovre
  • 5.7 Avastin
  • 5.8 Other products

Chapter 6 Market Estimates and Forecast, By Disease Type, 2021 - 2032 ($ Mn)

  • 6.1 Key trends
  • 6.2 Wet AMD
  • 6.3 Dry AMD

Chapter 7 Market Estimates and Forecast, By Age Group, 2021 - 2032 ($ Mn)

  • 7.1 Key trends
  • 7.2 50-64 years
  • 7.3 65-74 years
  • 7.4 75 and above

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

  • 8.1 Key trends
  • 8.2 Hospital pharmacies
  • 8.3 Specialty pharmacies
  • 8.4 E-commerce

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

  • 9.1 Key trends
  • 9.2 North America
    • 9.2.1 U.S.
    • 9.2.2 Canada
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 France
    • 9.3.4 Spain
    • 9.3.5 Italy
    • 9.3.6 Netherlands
  • 9.4 Asia Pacific
    • 9.4.1 China
    • 9.4.2 Japan
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 South Korea
  • 9.5 Latin America
    • 9.5.1 Brazil
    • 9.5.2 Mexico
    • 9.5.3 Argentina
  • 9.6 Middle East and Africa
    • 9.6.1 South Africa
    • 9.6.2 Saudi Arabia
    • 9.6.3 UAE

Chapter 10 Company Profiles

  • 10.1 Adverum Biotechnologies
  • 10.2 Alkeus Pharmaceuticals
  • 10.3 Amgen
  • 10.4 Astellas Pharma
  • 10.5 Bausch Health Companies
  • 10.6 Bayer AG
  • 10.7 Biogen
  • 10.8 Coherus BioSciences
  • 10.9 F. Hoffmann-La Roche
  • 10.10 Kodiak Sciences
  • 10.11 Novartis AG
  • 10.12 Pfizer
  • 10.13 Regeneron Pharmaceuticals
  • 10.14 Sandoz Group AG
  • 10.15 STADA Arzneimittel AG